Deficits in the miRNA-34a-regulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer's disease (AD); an update

Frontiers in Aging Neuroscience

Volumn 6, Issue JUN, 2014, Pages

  Bhattacharjee, Surjyadipta ^a   Zhao, Yuhai ^a   Lukiw, Walter J ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloidosis; Innate immune response; miRNA 34a; Phagocytosis; TREM2

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; MEMBRANE PROTEIN; MICRORNA 34A; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BONE FRAGILITY; BONE MARROW CELL; BRAIN INJURY; CELL SURFACE; CELL SURVIVAL; DOWN REGULATION; GENETIC ASSOCIATION; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LOSS OF FUNCTION MUTATION; MICROGLIA; NERVE DEGENERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRESENILE DEMENTIA; PROTEIN DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

EID: 84904542042     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00116     Document Type: Article

References (57)

1. Abduljaleel, Z., Al-Allaf, F. A., Khan, W., Athar, M., Shahzad, N., Taher, M. M., et al. (2014). Evidence of TREM2 variant associated with triple risk of Alzheimer's disease. PLoS ONE 9:e92648. doi: 10.1371/journal.pone.0092648
2. Agostini, M., and Knight, R. A. (2014). miR-34: from bench to bedside. Oncotarget 5, 872-881.
3. Agostini, M., Tucci, P., Killick, R., Candi, E., Sayan, B. S., Rivetti di Val Cervo, P., et al. (2011). Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc. Natl. Acad. Sci. U.S.A. 108, 21093-21098. doi: 10.1073/pnas.1112061109
4. Alexandrov, P. N., Dua, P., Hill, J. M., Bhattacharjee, S., Zhao, Y., and Lukiw, W. J. (2012). microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol. 3, 365-373.
5. Alexandrov, P. N., Zhao, Y., Jones, B. M., Bhattacharjee, S., and Lukiw, W. J. (2013). Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a in a murine microglial cell line. J. Inorg. Biochem. 128, 267-269. doi: 10.1016/j.jinorgbio.2013.05.010
6. Bagyinszky, E., Youn, Y. C., An, S. S., and Kim, S. (2014). The genetics of Alzheimer's disease. Clin. Interv. Aging 9, 535-551. doi: 10.2147/CIA.S51571
7. Benitez, B. A., Cruchaga, C., and United States-Spain Parkinson's Disease Research Group. (2013). TREM2 and neurodegenerative disease. N. Engl. J. Med. 369, 1567-1568. doi: 10.1056/NEJMc1306509#SA4
8. Bhatnagar, S., Chertkow, H., Schipper, H. M., Yuan, Z., Shetty, V., Jenkins, S., et al. (2014). Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma. Front. Mol. Neurosci. 7:2. doi: 10.3389/fnmol.2014.00002
9. Blennow, K., de Leon, M. J., and Zetterberg, H. (2006). Alzheimer's disease. Lancet 368, 387-403. doi: 10.1016/S0140-6736(06)69113-7
10. Boon, R. A., Lekushi, K., Lechner, S., Seeger, T., Fischer, A., Heydt, S., et al. (2013). MicroRNA-34a regulates cardiac ageing and function. Nature 495, 107-110. doi: 10.1038/nature11919
11. Boutajangout, A., and Wisniewski, T. (2013). The innate immune system in Alzheimer's disease. Int. J. Cell Biol. 2013:576383. doi: 10.1155/2013/576383
12. Cady, J., Koval, E. D., Benitez, B. A., Zaidman, C., Jockel-Balsarotti, J., Allred, P., et al. (2014). TREM2 Variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 71, 449-453. doi: 10.1001/jamaneurol.2013.6237
13. Chang, C. C., Althaus, J. C., Carruthers, C. J., Sutton, M. A., Steel, D. G., and Gafni, A. (2013). Synergistic interactions between Alzheimer's Aß40 and Aß42 on the surface of primary neurons revealed by single molecule microscopy. PLoS ONE 8:e82139. doi: 10.1371/journal.pone.0082139
14. Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., et al. (2008). Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis. 14, 27-41. doi: 10.1016/j.jalz.2008.05.420
15. Crampton, S. J., and O'Keeffe, G. W. (2013). NF-κB: emerging roles in hippocampal development and function. Int. J. Biochem. Cell Biol. 45, 1821-1824. doi: 10.1016/j.biocel.2013.05.037
16. Dorval, V., Nelson, P. T., and Hébert, S. S. (2013). Circulating microRNAs in Alzheimer's disease: the search for novel biomarkers. Front. Mol. Neurosci. 6:24. doi: 10.3389/fnmol.2013.00024
17. Forabosco, P., Ramasamy, A., Trabzuni, D., Walker, R., Smith, C., Bras, J., et al. (2013). Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol. Aging 34, 2699-2714. doi: 10.1016/j.neurobiolaging.2013.05.001
18. Gonzalez Murcia, J. D., Schmutz, C., Munger, C., Perkes, A., Gustin, A., Peterson, M., et al. (2013). Assessment of TREM2 rs75932628 association with Alzheimer's disease in a population-based sample: the Cache County Study. Neurobiol. Aging 34, 2889.e11-2889.e13. doi: 10.1016/j.neurobiolaging.2013.06.004
19. Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., et al. (2013). Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631-643. doi: 10.1016/j.neuron.2013.04.014
20. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., et al. (2013). TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127. doi: 10.1056/NEJMoa1211851
21. Guo, H., Ingolia, N. T., Weissman, J. S., and Bartel, D. P. (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840. doi: 10.1038/nature09267
22. Hampel, H., and Lista, S. (2013). Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease? Alzheimers Res. Ther. 5:11. doi: 10.1186/alzrt165
23. Henshall, D. C. (2014). MicroRNA and epilepsy: profiling, functions and potential clinical applications. Curr. Opin. Neurol. 27, 199-205. doi: 10.1097/WCO.0000000000000079
24. Hickman, S. E., and El Khoury, J. (2014). TREM2 and the neuroimmunology of Alzheimer's disease. Biochem. Pharmacol. 88, 495-498. doi: 10.1016/j.bcp.2013.11.021
25. Hill, J. M., Bhattacharjee, S., Pogue, A. I., and Lukiw, W. J. (2014b). The gastrointestinal (GI) tract microbiome and potential link to Alzheimer's disease (AD). Front. Neurol. 5:43. doi: 10.3389/fneur.2014.00043
26. Hill, J. M., Zhao, Y., Bhattacharjee, S., and Lukiw, W. J. (2014a). miRNAs and viroids utilize common strategies in genetic signal transfer. Front. Mol. Neurosci. 7:10. doi: 10.3389/fnmol.2014.00010
27. Jiang, T., Yu, J. T., Zhu, X. C., and Tan, L. (2013). TREM2 in Alzheimer's disease. Mol. Neurobiol. 48, 180-185. doi: 10.1007/s12035-013-8424-8
28. Jiang, T., Yu, J. T., Zhu, X. C., Tan, M. S., Gu, L. Z., Zhang, Y. D., et al. (2014). Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiol. Aging 35, 1243-1251. doi: 10.1016/j.neurobiolaging.2013.11.026
29. Jones, B. M., Bhattacharjee, S., Dua, P., Hill, J. M., Zhao, Y., and Lukiw, W. J. (2014). Regulating amyloidogenesis through the natural triggering receptor expressed in myeloid/microglial cells 2 (TREM2). Front. Cell. Neurosci. 8:94. doi: 10.3389/fncel.2014.00094
30. Junker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R., et al. (2009). MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132, 3342-3352. doi: 10.1093/brain/awp300
31. Kawabori, M., Hokari, M., Zheng, Z., Kim, J. Y., Calosing, C., Hsieh, C. L., et al. (2013). Triggering receptor expressed on myeloid cells-2 correlates to hypothermic neuroprotection in ischemic stroke. Ther. Hypothermia Temp. Manag. 3, 189-198. doi: 10.1089/ther.2013.0020
32. Lagos-Quintana, M., Rauhut, R., Lendeckel, W., and Tuschl, T. (2001). Identification of novel genes coding for small expressed RNAs. Science 294, 853-858. doi: 10.1126/science.1064921
33. Lattante, S., Le Ber, I., Camuzat, A., Dayan, S., Godard, C., Van Bortel, I., et al. (2013). TREM2 mutations are rare in a French cohort of patients with frontotemporal dementia. Neurobiol. Aging 34, 2443.e1-2443.e2. doi: 10.1016/j.neurobiolaging.2013.04.030
34. Li, X., Khanna, A., Li, N., and Wang, E. (2011). Circulatory miR34a as an RNA-based, noninvasive biomarker for brain aging. Aging (Albany NY) 3, 985-1002.
35. Lukiw, W. J. (2007). Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 18, 297-300. doi: 10.1097/WNR.0b013e3280148e8b
36. Lukiw, W. J. (2012). NF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease. Alzheimers Res. Ther. 4, 47. doi: 10.1186/alzrt150
37. Lukiw, W. J. (2013a). Antagonism of NF-κB-up-regulated micro RNAs (miRNAs) in sporadic Alzheimer's disease (AD): anti-NF-κB vs. anti-miRNA strategies. Front. Genet. 4:77. doi: 10.3389/fgene.2013.00077
38. Lukiw, W. J. (2013b) Variability in micro RNA (miRNA) abundance, speciation and complexity amongst different human populations and potential relevance to Alzheimer's disease (AD). Front. Cell. Neurosci. 7:133. doi: 10.3389/fncel.2013.00133
39. Lukiw, W. J., Zhao, Y., and Cui, J. G. (2008). An NF-κB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J. Biol. Chem. 283, 31315-31322. doi: 10.1074/jbc.M805371200
40. Ma, J., Zhou, Y., Xu, J., Liu, X., Wang, Y., Deng, Y., et al. (2014). Association study of TREM2 polymorphism rs75932628 with late-onset Alzheimer's disease in Chinese Han population. Neurol. Res. 13:1743132814Y0000000376. doi: 10.1179/1743132814Y.0000000376
41. Maffioletti, E., Tardito, D., Gennarelli, M., and Bocchio-Chiavetto, L. (2014). Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Front. Cell. Neurosci. 8:75. doi: 10.3389/fncel.2014.00075
42. Mager, P. P. (1998). Molecular simulation of the primary and secondary structures of the Abeta (1-42)-peptide of Alzheimer's disease. Med. Res. Rev. 18, 403-430.
43. Miyashita, A., Wen, Y., Kitamura, N., Matsubara, E., Kawarabayashi, T., Shoji, M., et al. (2014). Lack of genetic association between TREM2 and late-onset Alzheimer's disease in a Japanese population. J. Alzheimers Dis. doi: 10.3233/JAD-140225. [Epub ahead of print].
44. Nataf, S., Anginot, A., Vuaillat, C., Malaval, L., Fodi, L. N., Chereul, E., et al. (2005). Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am. J. Pathol. 166, 275-286. doi: 10.1016/S0002-9440(10)62251-1
45. Neumann, H., and Daly, M. J. (2013). Variant TREM2 as risk factor for Alzheimer's disease. N. Engl. J. Med. 368, 182-184. doi: 10.1056/NEJMe1213157
46. Olson, M. V. (2012). Human genetic individuality. Annu. Rev. Genomics Hum. Genet. 13, 1-27. doi: 10.1146/annurev-genom-090711-163825
47. Raj, A., Rifkin, S. A., Andersen, E., and van Oudenaarden, A. (2010). Variability in gene expression underlies incomplete penetrance. Nature 463, 913-918. doi: 10.1038/nature08781
48. Rosenthal, S. L., and Kamboh, M. I. (2014). Late-onset Alzheimer's disease genes and the potentially implicated pathways. Curr. Genet. Med. Rep. 2, 85-101. doi: 10.1007/s40142-014-0034-x
49. Satoh, J., Shimamura, Y., and Tabunoki, H. (2011). Gene expression profile of THP-1 monocytes following knockdown of DAP12, a causative gene for Nasu-Hakola disease. Cell. Mol. Neurobiol. 32, 337-343. doi: 10.1007/s10571-011-9769-z
50. Schipper, H. M., Maes, O. C., Chertkow, H. M., and Wang, E. (2007). MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul. Syst. Bio. 1, 263-274.
51. Sieber, M. W., Jaenisch, N., Brehm, M., Guenther, M., Linnartz-Gerlach, B., and Neumann, H. (2013). Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS ONE 8:e52982. doi: 10.1371/journal.pone.0052982
52. Stine, W. B. Jr. Dahlgren, K. N., Krafft, G. A., and LaDu, M. J. (2003). In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278, 11612-11622. doi: 10.1074/jbc.M210207200
53. Vossel, K. A., Beagle, A. J., Rabinovici, G. D., Shu, H., Lee, S. E., Naasan, G., et al. (2013). Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 70, 1158-1166. doi: 10.1001/jamaneurol.2013.136
54. Wang, X., Liu, P., Zhu, H., Xu, Y., Ma, C., Dai, X., et al. (2009). miRNA-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res. Bull. 80, 268-273. doi: 10.1016/j.brainresbull.2009.08.006
55. Watson, D., Castaño, E., Kokjohn, T. A., Kuo, Y. M., Lyubchenko, Y., Pinsky, D., et al. (2005). Physicochemical characteristics of soluble oligomeric Aß and their pathologic role in Alzheimer's disease. Neurol. Res. 27, 869-881. doi: 10.1179/016164105X49436
56. Zhao, Y., Bhattacharjee, S., Jones, B. M., Dua, P., Alexandrov, P. N., Hill, J. M., et al. (2013). Regulation of TREM2 expression by an NF-êB-sensitive miRNA-34a. Neuroreport 24, 318-323. doi: 10.1097/WNR.0b013e32835fb6b0
57. Zhao, Y., and Lukiw, W. J. (2013). TREM2 signaling, miRNA-34a and the extinction of phagocytosis. Front. Cell. Neurosci. 7:131. doi: 10.3389/fncel.2013.00131